| --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Developing treatments | | | | | designed to have a clear and profound impact for patients with rare diseases, including WHIM syndrome and uncommon cancers | | | | | September 2021 Investor Deck | | | | | | | | | Forward-Looking Statements 2 This presentation contains forward-looking statements within the mea ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Carey Gallant - Investor Relations, LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Conference Call Participants Trevor Allred - Oppenheimer RK - H.C. Wainwright Zegbeh Jallah - ROTH Capital Partners Mayank Mamtani - B. Riley Financial Ben Shim - Canaccord. Operator Greetings, and welcome to X4 Pharmaceutic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Marc Frahm - Cowen Swayampakula Ramakanth - H.C. Wainwright Sahil Kazmi - B. Riley FBR Arlinda Lee - Canaccord Genuity Operator Greetings and welcome to X4 Pharmaceuticals First Quarter Financial a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________ (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 ________________________________________________________________________________________ ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2020 Results Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Dr. Diego Cadavid - Chief Medical Officer Art Taveras - Chief Scientific Officer Mary DiBiase - Senior Vice-President, Technical Operations and Quality Conference Call Participants Stephen Willey - Stifel Joel Beatty - Citi Leland Gershell - Oppenheimer Swayampakula Ramakanth ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Candice Ellis - Director of Corporate Communications and Investment Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Arlinda Lee - Canaccord Laura Christianson - Cowen Zegbeh Jallah - ROTH Capital Operator Greetings and welcome to X4 Pharmaceuticals Third Quarter Financial and Operating Results Conference Call. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

INVESTOR PRESENTATION SEPTEMBER 2020 X4 PHARMACEUTICALS INVESTOR DECK FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candidates or to expand our ...